OIRA Conclusion of EO 12866 Regulatory Review


RIN: 0938-AT91         View EO 12866 Meetings Received Date: 06/20/2019 
Title: International Pricing Index Model For Medicare Part B Drugs (CMS-5528-P) 
Agency/Subagency: HHS / CMS   Stage: Interim Final Rule 
Concluded Action: Consistent with Change  Concluded Date: 11/19/2020 
Legal Deadline: None  Economically Significant: Yes 
Publication Date:   Unfunded Mandates: No 
Major: Yes  Related To Homeland Security: No 
Regulatory Flexibility Analysis Required: Yes  Small Entities Affected: Businesses 
Federalism Implications: No  Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: Yes Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: No